The Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) said on Monday, May 3, that the clinical trial on the use of Ivermectin as a treatment for coronavirus disease (COVID-19) will involve patients with "non-severe” or those with mild to moderate cases.
DOST-PCHRD Executive Director Dr. Jaime C. Montoya said the research team from the University of the Philippines (UP) Manila- Philippine General Hospital (PGH), headed by Dr. Aileen Wang, is now drafting the research protocol, which includes the timeline of the clinical trial and the target participants.
He said the protocol will have to be submitted to the DOST and the Food and Drug Administration (FDA) for approval.
"Ang isasama sa ating pagaaral ay yung tinatawag na non-severe so ito po ay mild to moderate cases, symptomatic cases at pati po asymptomatic 'yung walang nararamdaman na karamihan na nakikita sa mga quarantine facility (Those who will be included in the clinical trial are those non-severe, these are mild to moderate cases, symptomatic cases as well as the asymptomatic, those who do not experience the symptoms and most of whom we see in the quarantine facilities),” Montoya said during the Laging Handa briefing on Monday.
He noted that most of the COVID-19 cases in the country were mild to moderate cases.
“Nakikita po natin na ito ang bagay na gawan natin ng pagaaral sa ngayon para kung saka- sakali may benepisyo ang Ivermectin mas malaking makikinabang na populasyon (We see that this is what we are going to study right now so that in case Ivermectin has a benefit, a larger population will benefit),” he said.
Montoya maintained that the country is targeting to conduct its Ivermectin clinical trial by end of May or first week of June.
https://mb.com.ph/2021/04/23/title-53/